Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crisaborole versus pimecrolimus in children with mild to moderate atopic dermatitis
ChiCTR2200060584Phase 4Recruiting
- Sponsor
- Shenzhen Children's Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in atopic dermatitis (AD) comparing Crisaborole group with Pimecrolimus group (2 arms). Primary endpoint: Percentage of patients with Investigator’s Static Global Assessment (ISGA) success. Started Mar 2022; status: recruiting.
02
Drugs
crisaborolepimecrolimus
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2200060584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060584.